Genitourinary: RMC-6236-401 (EAP)
Trial ID
07573215
Trial Sponsor
Revolution Medicines, Inc.
Study Name: Expanded Access Program to Treat Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma with Daraxonrasib
Study Name: Expanded Access Program to Treat Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma with Daraxonrasib